Dafna Capital Management LLC Affimed N.V. Transaction History

Dafna Capital Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$2.27 - $4.86 $261,050 - $558,900	115,000 Added 20.13%	686,282 $1.9 Million
Q4 2021 Feb 14, 2022	SELL	$5.37 - $7.07 $2.11 Million - $2.78 Million	-393,575 Reduced 40.79%	571,282 $3.15 Million
Q2 2021 Aug 16, 2021	SELL	$7.78 - $11.4 $194,500 - $285,000	-25,000 Reduced 2.53%	964,857 $8.2 Million
Q1 2021 May 17, 2021	BUY	$5.12 - $8.48 $591,360 - $979,440	115,500 Added 13.21%	989,857 $7.83 Million
Q4 2020 Feb 16, 2021	SELL	$3.16 - $7.03 $157,750 - $350,944	-49,921 Reduced 5.4%	874,357 $5.09 Million
Q3 2020 Nov 16, 2020	BUY	$3.26 - $4.73 $258,446 - $374,984	79,278 Added 9.38%	924,278 $3.13 Million
Q2 2020 Aug 14, 2020	SELL	$1.58 - $4.63 $455,673 - $1.34 Million	-288,401 Reduced 25.45%	845,000 $3.9 Million
Q1 2020 May 15, 2020	SELL	$1.44 - $3.02 $227 - $477	-158 Reduced 0.01%	1,133,401 $1.79 Million
Q4 2019 Feb 14, 2020	BUY	$2.25 - $3.07 $2.55 Million - $3.48 Million	1,133,559 New	1,133,559 $3.11 Million

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Dafna Capital Management LLC with notifications on news.